BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Agennix Inc. 

7505 Fannin Street
Suite 510
Houston  Texas  77054  U.S.A.
Phone: 713-796-1091 Fax: 713-796-1044


SEARCH JOBS


Industry
Biotechnology






 Company News
Agennix AG Reports Financial Results for Second Quarter and First Half of 2012 7/31/2012 9:16:30 AM    More...
Stem Cell Innovations to Provide Research and Assay Services to Agennix Inc. 3/2/2010 9:10:02 AM    More...
Agennix Inc. Expands Talactoferrin Phase 3 FORTIS-M Registration Trial Globally 1/21/2010 10:58:56 AM    More...
GPC Biotech AG (GPCG.DE) Provides Update on Merger with Agennix Inc. 10/8/2009 10:15:19 AM    More...
Agennix Receives Fast Track Designation From FDA for Talactoferrin in Combination With Sunitinib for Renal Cell Carcinoma 5/19/2009 7:24:50 AM    More...
GPC Biotech AG (GPCG.DE) and Agennix Announce Proposed Merger 2/18/2009 7:46:36 AM    More...
Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis 4/22/2008 8:20:45 AM    More...
Agennix's Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer 2/26/2008 6:34:34 AM    More...
Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer Trial 1/17/2008 6:33:57 AM    More...
Survival Benefit Demonstrated in Placebo-Controlled Trial in Patients with Refractory Non-Small Cell Lung Cancer Treated with Agennix's Oral Talactoferrin 6/4/2007 11:30:08 AM    More...
123

//-->